Neochromosome, Inc. (EFL Life Sciences, ’20) announces partnership with Sumitovant Biopharma, Inc. to accelerate protein drug discovery and improve manufacturing. This collaboration combines Neochromosome’s neoYeast™ platform with Sumitovant’s DrugOME™ computational ecosystem to identify novel proteins that would benefit from man-made non-canonical amino acid chemistries.
Neochromsomone, led by Leslie Mitchell, uses synthetic biology technologies to create entire chromosomes designed de novo to be modular and orthogonal to the host cell.
